Texas abortion ruling could undermine FDA

A legal challenge to FDA’s approval of abortion drug mifepristone could have broad implications for the agency and drug companies, undermining the agency’s authority and introducing uncertainty that could chill investments in drug development, according to legal scholars.

Alarms are ringing at FDA, where agency officials believe a loss in the case could open the door for legal challenges by members of the public who disagree with its decisions, drug manufacturers seeking to knock competitors out of the market, and groups with ideological agendas...